Compare Sana Biotechnology Inc (SANA) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs SAP SE — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: SAP SE is far larger — about 285.2× Sana Biotechnology Inc's market cap, and SAP SE pays a 1.38% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and SAP SE for 118 Days on average.
| SANA | SAP | |
|---|---|---|
Market Cap | $836.71M | $238.67B |
Volume | 4,507,444 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $5.92 | $280.46 |
52-Week Low | $2.68 | $146.38 |
Typical Hold Time | 23 Days | 118 Days |
Enterprise Value | $749.96M | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
SAP trades at $212.4, up 1.08% today, with a bullish technical signal and strong fundamentals. Revenue grew to $36.8B in 2025, with net income of $7.16B and a 20.41% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $253.40 price target. Cloud revenue growth and AI initiatives are key drivers, though competition and margin pressures pose risks.
The outlook is positive, supported by robust cash flow and a €10B buyback program. Upside potential exists if AI and cloud strategies deliver, but execution risks and market volatility could hinder gains. Investors should weigh strong profitability against sector headwinds and valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
